1-溴-3-氯-2,5-二氟苯 | 1160573-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-3-氯-2,5-二氟苯
• 英文名称: 1-bromo-3-chloro-2,5-difluorobenzene
• CAS: 1160573-67-0
• 化学式: C₆H₂BrClF₂
• 分子量: 227.436
• InChiKey: ZXJZOLQKJFVXSE-UHFFFAOYSA-N

物化性质

• 沸点：
  191.0±35.0 °C(Predicted)
• 密度：
  1.805±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-溴-3-氯-2,5-二氟苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 potassium acetate 、 potassium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 水 为溶剂， 反应 13.0h， 生成
  参考文献：
  名称：

  ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

  摘要：

  提供的是有机金属化合物，还提供了包含这些有机金属化合物的配方。此外，还提供了使用这些有机金属化合物的OLED和相关消费品。

  公开号：

  US20200392172A1

文献信息

• [EN] ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE<br/>[FR] ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DE RORΓ ET POUR LE TRAITEMENT DE MALADIES
  申请人：LYCERA CORP

  公开号：WO2016201225A1

  公开（公告）日：2016-12-15

  The invention provides aryl dihydro-2H-benzo[b] [l,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

  这项发明提供了芳基二氢-2H-苯并[b][1,4]噁嗪磺胺和相关化合物、药物组合物、促进RORγ活性的方法、增加受试者体内IL-17含量的方法，以及利用这些化合物治疗癌症和其他医学疾病的方法。
• Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
  申请人：Lycera Corporation

  公开号：US10611740B2

  公开（公告）日：2020-04-07

  The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

  本发明提供了芳基二氢-2H-苯并[b][1,4]恶嗪磺酰胺及相关化合物、药物组合物、促进 RORy 活性的方法、增加受试者体内 IL-17 数量的方法以及使用此类化合物治疗癌症和其他疾病的方法。
• Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
  申请人：The Regents of the University of Michigan

  公开号：US11059796B2

  公开（公告）日：2021-07-13

  The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

  本发明提供了芳基二氢-2H-苯并[b][1,4]恶嗪磺酰胺及相关化合物、药物组合物、促进 RORγ 活性的方法、增加受试者体内 IL-17 数量的方法以及使用此类化合物治疗癌症和其他疾病的方法。
• Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists
  作者：Jason M. Cox、Hong D. Chu、Mariappan V. Chelliah、John S. Debenham、Keith Eagen、Ping Lan、Matthew Lombardo、Clare London、Michael A. Plotkin、Unmesh Shah、Zhongxiang Sun、Henry M. Vaccaro、Srikanth Venkatraman、Takao Suzuki、Nengxue Wang、Eric R. Ashley、Alejandro Crespo、Maria Madeira、Dennis H. Leung、Candice Alleyne、Aimie M. Ogawa、Sarah Souza、Brande Thomas-Fowlkes、Jerry Di Salvo、Adam Weinglass、Melissa Kirkland、Michele Pachanski、Mary Ann Powles、Effie Tozzo、Taro E. Akiyama、Feroze Ujjainwalla、James R. Tata、Christopher J. Sinz

  DOI：10.1021/acsmedchemlett.6b00360

  日期：2017.1.12

  Type 2 diabetes mellitus (T2DM) is an ever increasing worldwide epidemic, and the identification of safe and effective insulin sensitizers, absent of weight gain, has been a long-standing goal of diabetes research. G-protein coupled receptor 120 (GPR120) has recently emerged as a potential therapeutic target for treating T2DM. Natural occurring, and more recently, synthetic agonists have been associated with insulin sensitizing, anti-inflammatory, and fat metabolism effects. Herein we describe the design, synthesis, and evaluation of a novel spirocyclic GPR120 agonist series, which culminated in the discovery of potent and selective agonist 14. Furthermore, compound 14 was evaluated in vivo and demonstrated acute glucose lowering in an oral glucose tolerance test (oGTT), as well as improvements in homeostatic measurement assessment of insulin resistance (HOMA-IR; a surrogate marker for insulin sensitization) and an increase in glucose infusion rate (GIR) during a hyperinsulinemic euglycemic clamp in diet-induced obese (DIO) mice.
• ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
  申请人：Lycera Corporation

  公开号：EP3307738A1

  公开（公告）日：2018-04-18